We have a proven track record of success in drug discovery, drug development, FDA approval and commercialization.


Michela Gallagher, PhD
Founder and CEO

Michela Gallagher, PhD founded AgeneBio in 2008 and currently serves as CEO. Her research led to the discovery of neural overactvity in neurocognitive aging localized to specific circuits in the hippocampus. She led the Phase 2 trial of AGB101 and initiation of AgeneBio’s drug discovery program to develop selective GABA alpha 5 positive allosteric modulators.

Michela Gallagher, PhD is the Krieger-Eisenhower Professor of Psychological and Brain Science, heads the Neurogenetics and Behavior Center at Johns Hopkins University and has published over 250 peer-reviewed papers in the field of cognitive neuroscience. She is a Fellow of the American Association for the Advancement of Science, the American Psychological Association, the American Psychological Society. She is the 2018 recipient of the Melvin R. Goodes Prize for a lifelong commitment to Alzheimer’s drug discovery and development. She was the 2014 recipient of the Society for Neuroscience, Mika Salpeter Lifetime Achievement Award. Her work has been recognized by the American Psychological Association, D.O. Hebb Distinguished Scientific Contribution Award in 2010, a Freedom to Discover Award from the Bristol-Myers Foundation (2003-2008), and Senior Scientist Award from the Ellison Medical Foundation (2008-2012). She has served the on Boards of Scientific Counselors at the National Institute of Mental Health and the National Institute on Aging and currently serves on the Advisory Board of DZNE the German Center for Neurodegenerative Diseases.

Prior to joining Johns Hopkins in 1997, Dr. Gallagher rose through the faculty ranks at University of North Carolina at Chapel Hill, where she was the Kenan Professor of Psychology. She earned her PhD in Physiological Psychology from University of Vermont and in 1968 earned her undergraduate degree from Colgate University as one of two women in the university’s first female graduating class.


Sharon Rosenzweig-Lipson, PhD
Vice President of Research and Development

Sharon Rosenzweig-Lipson, PhD, has served as our Vice President of Research and Development since 2011. Dr. Rosenzweig-Lipson offers AgeneBio expertise in screening strategies, in vivo models, translation and clinical development strategy with more than 25 years of experience developing compounds for psychiatric and neurologic indications in the pharmaceutical industry.

Dr. Rosenzweig-Lipson’s work with AgeneBio has been integral to the AGB101 clinical program. She led the development of the proprietary formulation of AGB101, management of the Phase 1 with FDA review and completed manufacture of medical supplies for the Phase 3 program. She is currently Project Director of the HOPE4MCI trial. She also leads the GABA-A a5 PAM discovery program and manages the Blueprint collaboration (government, academic, CRO).

Sharon spent her career focused on psychiatric and neurologic indications in the pharmaceutical industry, including American Cyanamid, American Home Products, Wyeth and Pfizer. She led numerous drug discovery and drug development teams from the earliest exploratory stages through a successful Phase 2 Proof of Concept in Schizophrenia. She earned her PhD in Behavioral Neuroscience from Harvard University.


Richard Mohs, PhD
Vice President of Clinical Development

Richard Mohs, PhD, has served as our Vice President of Clinical Development since December 2015. Dr. Mohs offers more than 30 years of experience in neuroscience clinical development and led Eli Lilly’s Phase 3 development team for Alzheimer’s disease drug candidates solanezumab and semagacestat.

Dr. Mohs now leads the AgeneBio Phase 3 team on the efficacy of AGB101 in patients with MCI due to AD. He is also P.I. on a NIIH award supporting a substudy in the Phase 3 trial to include biomarker development using [18F]MK-6420 for tau PET imaging.

Dr. Mohs served as Eli Lilly’s Vice President for Neuroscience Early Clinical Development and Distinguished Research Fellow within Lilly Research Laboratories, where he led a clinical development team targeting Alzheimer’s disease or other neurodegenerative diseases, pain, depression or schizophrenia. Previously, he was Professor in the Department of Psychiatry with the Mount Sinai School of Medicine and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Center. During this time, he was instrumental in designing clinical trials that led to the approval in the US and other countries of cholinergic drug treatments for Alzheimer’s disease. He has served as an advisor to many neuroscience research programs at universities in the United States and to several foundations supporting neuroscience research including the John D. and Catherine T. MacArthur Foundation, the Charles A. Dana Foundation and has recently been appointed to the Board of Governors for the Alzheimer’s Drug Discovery Foundation.

Dr. Mohs received his PhD in psychology from Stanford University and completed postdoctoral training in pharmacology at the Stanford University Medical School.


Russell Barton
Director of Clinical Operations

Russ Barton spent his career of over 38 years at Eli Lilly and Company and served for the last 10 years as Director of Operations for the Global AD team. In that capacity he was the Director of Clinical Operations on 5 Phase 3 trials in Alzheimer’s disease. He joined AgeneBio at Director of Clinical Operations for the AGB101 Phase 3 trial, now underway.

Sarita Foster

Sarita Foster
Director of Business Operations

Sarita Foster has served as our Director of Business Operations since June 2014. Sarita offers more than 25 years of experience in accounting and finance. Prior to joining AgeneBio, she served in senior finance positions for more than 10 years at Johns Hopkins University, most recently as Assistant Dean, Financial Operations at the Zanvyl Krieger School of Arts and Sciences. Previously, she served as Controller for Martin Marietta Laboratories. She earned an MBA from Loyola University and a BS from the University of Virginia and is licensed as a non-practicing CPA.